Home LiteratureArticle Details
PMID: 21725855 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

Elevated expression of macrophage migration inhibitory factor correlates with tumor recurrence and poor prognosis of patients with gliomas.

Journal of neuro-oncology ·Vol. 106 ·No. 1 ·2012-01-00 ·Pages 43-51

Wang XB, Tian XY, Li Y, Li B, Li Z

Abstract

Macrophage migration inhibitory factor (MIF) plays a critical role in tumorigenesis. We aim to examine the association of MIF with tumor recurrence and survival of gliomas, and to determine whether MIF is a valuable prognostic predictor for glioma patients. The expression of MIF and interleukin 8 (IL-8) was evaluated in 36 high-grade gliomas (20 glioblastoma multiforme, 13 anaplastic astrocytoma, and 3 anaplastic oligoastrocytoma) and 32 low-grade gliomas (18 fibrillary astrocytoma, 5 pilocytic astrocytoma, 5 oligodendroglioma, 3 ependymoma and 1 pleomorphic xanthoastrocytoma) by immunostaining. Intratumoral microvessel density (IMD) of tumors in relation to immunostainings and clinicopathological factors were analyzed statistically as well as the follow-up data of patients. High expression of both MIF (58.8%) and IL-8 (52.9%) was significantly associated with high-grade gliomas and increased microvessels in tumors, but only high expression of MIF was closely related to tumor recurrence (P = 0.001). High expression of IL-8 exhibited a close correlation with high expression of MIF in tumors (P = 0.001). Histological grading, high expression of MIF and IL-8 correlated with patients' overall survival in univariate analysis. However, only histological grading and MIF expression exhibited a relationship with survival of patients as independent prognostic factors of glioma by multivariate analysis; the hazard ratios were 28.012 (P = 0.001) and 11.782 (P = 0.001), respectively. Elevated production of MIF in glioma tumor cells may contribute to tumor recurrence and a worse prognosis. MIF may serve as an independent predictive factor for prognosis of glioma patients.

MeSH Terms
Adolescent Adult Aged Brain Neoplasms/blood supply,genetics,pathology Capillaries/pathology Child Female Follow-Up Studies Genetic Markers Glioma/blood supply,genetics,pathology Humans Immunohistochemistry Interleukin-8/biosynthesis,genetics Kaplan-Meier Estimate Macrophage Migration-Inhibitory Factors/biosynthesis Male Middle Aged Neoplasm Recurrence, Local/genetics Neovascularization, Pathologic/pathology Predictive Value of Tests Prognosis Regression Analysis Survival Young Adult
Chemicals
Genetic Markers Interleukin-8 Macrophage Migration-Inhibitory Factors
Authors & Affiliations
5 authors, click to expand affiliations / ORCID
Wang Xiao-Bing
Department of Pathology, Guangdong General Hospital, 106, Zhongshan Road II, Guangzhou, China.
Tian Xiao-Ying
Li Yang
Li Bin
Li Zhi
References (38)
38 references, click to expand
  1. Osteopontin and interleukin-8 expression is independently associated with prostate cancer recurrence.
    Clin Cancer Res. 2008 Jul 1;14(13):4111-8 PMID: 18593988
  2. HIF-1 and NF-kappaB-mediated upregulation of CXCR1 and CXCR2 expression promotes cell survival in hypoxic prostate cancer cells.
    Oncogene. 2007 Nov 15;26(52):7333-45 PMID: 17533374
  3. The role of macrophage inhibitory factor in tumorigenesis and central nervous system tumors.
    Cancer. 2009 May 15;115(10):2031-40 PMID: 19326434
  4. Necrosis as a prognostic factor in glioblastoma multiforme.
    Cancer. 1996 Mar 15;77(6):1161-6 PMID: 8635139
  5. Macrophage migration inhibitory factor regulates proliferation of gastric cancer cells via the PI3K/Akt pathway.
    World J Gastroenterol. 2009 Nov 28;15(44):5541-8 PMID: 19938192
  6. Macrophage migration inhibitory factor (MIF) promotes cell survival by activation of the Akt pathway and role for CSN5/JAB1 in the control of autocrine MIF activity.
    Oncogene. 2007 Aug 2;26(35):5046-59 PMID: 17310986
  7. Overexpression of macrophage migration inhibitory factor induces angiogenesis and deteriorates prognosis after radical resection for hepatocellular carcinoma.
    Cancer. 2005 Feb 1;103(3):588-98 PMID: 15612021
  8. A proinflammatory cytokine inhibits p53 tumor suppressor activity.
    J Exp Med. 1999 Nov 15;190(10):1375-82 PMID: 10562313
  9. Sustained mitogen-activated protein kinase (MAPK) and cytoplasmic phospholipase A2 activation by macrophage migration inhibitory factor (MIF). Regulatory role in cell proliferation and glucocorticoid action.
    J Biol Chem. 1999 Jun 18;274(25):18100-6 PMID: 10364264
  10. Long-term outcome of postoperative irradiation in patients with newly diagnosed WHO grade III anaplastic gliomas.
    Tumori. 2009 May-Jun;95(3):317-24 PMID: 19688970
  11. Macrophage migration inhibitory factor up-regulates the expression of interleukin-8 messenger RNA in synovial fibroblasts of rheumatoid arthritis patients: common transcriptional regulatory mechanism between interleukin-8 and interleukin-1beta.
    Arthritis Rheum. 2004 May;50(5):1437-47 PMID: 15146413
  12. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
    N Engl J Med. 2005 Mar 10;352(10):987-96 PMID: 15758009
  13. Influence of interleukin-8 and interleukin-10 on sporadic colon cancer development and progression.
    Carcinogenesis. 2008 Aug;29(8):1572-80 PMID: 18628251
  14. Hypoxia-induced activation of p38 mitogen-activated protein kinase and phosphatidylinositol 3'-kinase signaling pathways contributes to expression of interleukin 8 in human ovarian carcinoma cells.
    Clin Cancer Res. 2004 Jan 15;10(2):701-7 PMID: 14760093
  15. Macrophage migration inhibitory factor (MIF) expression in human glioblastomas correlates with vascular endothelial growth factor (VEGF) expression.
    Neuropathol Appl Neurobiol. 2002 Dec;28(6):452-60 PMID: 12445161
  16. Modulation of MDR-1 gene by MIF and GSTpi with drug resistance generation in hormone independent prostate cancer.
    Arch Androl. 2006 Jul-Aug;52(4):283-91 PMID: 16728344
  17. The treatment of oligodendrogliomas and mixed oligodendroglioma-astrocytomas with PCV chemotherapy.
    J Neurosurg. 1992 May;76(5):741-5 PMID: 1564535
  18. Regulation of human lung adenocarcinoma cell migration and invasion by macrophage migration inhibitory factor.
    J Biol Chem. 2007 Oct 12;282(41):29910-8 PMID: 17709373
  19. Macrophage migration inhibitory factor stimulates angiogenic factor expression and correlates with differentiation and lymph node status in patients with esophageal squamous cell carcinoma.
    Ann Surg. 2005 Jul;242(1):55-63 PMID: 15973102
  20. Microvessel density correlates with lymph node metastases and prognosis in hilar cholangiocarcinoma.
    J Gastroenterol. 2008;43(12):959-66 PMID: 19107340
  21. Macrophage migration inhibitory factor and CXC chemokine expression in non-small cell lung cancer: role in angiogenesis and prognosis.
    Clin Cancer Res. 2003 Feb;9(2):853-60 PMID: 12576459
  22. Macrophage migration inhibitory factor contributes angiogenesis by up-regulating IL-8 and correlates with poor prognosis of patients with primary nasopharyngeal carcinoma.
    J Surg Oncol. 2010 Dec 1;102(7):844-51 PMID: 20872800
  23. Morphometric study of tumor angiogenesis as a new prognostic factor in nasopharyngeal carcinoma patients.
    Pathol Oncol Res. 2000;6(3):210-6 PMID: 11033462
  24. An essential role for macrophage migration inhibitory factor (MIF) in angiogenesis and the growth of a murine lymphoma.
    Mol Med. 1999 Mar;5(3):181-91 PMID: 10404515
  25. Up-regulation of macrophage migration inhibitory factor gene and protein expression in glial tumor cells during hypoxic and hypoglycemic stress indicates a critical role for angiogenesis in glioblastoma multiforme.
    Am J Pathol. 2003 Jan;162(1):11-7 PMID: 12507885
  26. Co-elevated expression of hepatocyte growth factor and Interleukin-8 contributes to poor prognosis of patients with primary nasopharyngeal carcinoma.
    Oncol Rep. 2010 Jan;23(1):141-50 PMID: 19956874
  27. Macrophage migration inhibitory factor evaluation compared with prostate specific antigen as a biomarker in patients with prostate carcinoma.
    Cancer. 2002 Mar 1;94(5):1449-56 PMID: 11920501
  28. Radiotherapy for high-grade gliomas. Does altered fractionation improve the outcome?
    Strahlenther Onkol. 2004 Jul;180(7):401-7 PMID: 15241527
  29. Hepatocyte growth factor suppresses tumor cell apoptosis in nasopharyngeal carcinoma by upregulating Bcl-2 protein expression.
    Pathol Res Pract. 2009;205(12):828-37 PMID: 19625133
  30. Macrophage migration inhibitory factor: roles in regulating tumor cell migration and expression of angiogenic factors in hepatocellular carcinoma.
    Int J Cancer. 2003 Oct 20;107(1):22-9 PMID: 12925952
  31. Role of MIF in inflammation and tumorigenesis.
    Oncology. 2008;75(3-4):127-33 PMID: 18791328
  32. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group.
    J Clin Oncol. 1999 Sep;17(9):2762-71 PMID: 10561351
  33. Macrophage migration inhibitory factor expression in cervical cancer.
    J Cancer Res Clin Oncol. 2010 May;136(5):651-7 PMID: 19915866
  34. Overexpression of macrophage migration inhibitory factor induces angiogenesis in human breast cancer.
    Cancer Lett. 2008 Mar 18;261(2):147-57 PMID: 18171602
  35. The interleukin-8 pathway in cancer.
    Clin Cancer Res. 2008 Nov 1;14(21):6735-41 PMID: 18980965
  36. Chemokines and glioma: invasion and more.
    J Neuroimmunol. 2010 Jul 27;224(1-2):8-12 PMID: 20656128
  37. Prognostic values of galectin-3 and the macrophage migration inhibitory factor (MIF) in human colorectal cancers.
    Mod Pathol. 2003 May;16(5):491-504 PMID: 12748256
  38. Macrophage migration inhibitory factor promotes tumor invasion and metastasis via the Rho-dependent pathway.
    Clin Cancer Res. 2005 Feb 1;11(3):1050-8 PMID: 15709171
Article Info
Journal
Journal of neuro-oncology
Abbr.
J Neurooncol
ISSN
1573-7373
DOI
10.1007/s11060-011-0640-3
Published
2012-01-00
Epub
2011-00-03
Pages
43-51
Language
English
Region
United States
NLM ID
8309335
Subset
IM
External Links
PubMed source DOI: 10.1007/s11060-011-0640-3 View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2